Skip to main content

Glucose Lowering Activity of Anvillea Radiata Coss & Durieu in Diabetic Rats

Buy Article:

$68.00 + tax (Refund Policy)

Introduction: Anvillea radiata Coss. & Durieu (Asteraceae) is an endemic plant from North Africa (Morocco and Algeria). This plant has many traditional uses including treatment of obesity and diabetes.

Aim of the Study: The study aims to evaluate the antidiabetic effect of aqueous extract of Anvillea radiata (A. radiata) leaves on both normal and streptozotocin (STZ)-induced diabetic rats treated at a dose of 10 mg/kg body weight for fifteen days. In addition, a preliminary pytochemical screening for various components was realized.

Results: The blood glucose levels were lowered in diabetic rats treated with A. radiata, but no effect was observed in normal rats. Single oral administration of A. radiata reduced blood glucose levels from 22.15±0.98 mmol/L to 14.00±1.89 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 22.15±0.98 mmol/L to 4.39±1.29 mmol/L (p< 0.0001) in STZ diabetic rats after fifteen days of treatment. According to the oral glucose tolerance test, the A. radiata (10 mg/kg) was shown to significantly prevent the increase in blood glucose levels in normal treated rats 30 min, 60 min and 120 min after glucose administration when compared to the control group. Concerning the preliminary phytochemical screening of A. radiata, several compounds of chemicals have been found such as polyphenols, flavonoids, tannins, mucilage, sesquiterpenes, terpenoids and carbohydrates.

Conclusion: The results show that aqueous extract of A. radiata leaves possesses a significant antihyperglycemic activity.

Keywords: Anvillea radiata; diabetes; oral glucose tolerance test; phytochemical screening; streptozotocin

Document Type: Research Article

Publication date: 01 April 2018

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content